What is Aptus Biotech?
Founded in 2010 through a collaboration with the Ramon y Cajal Hospital Foundation, Aptus Biotech aims to be a leader in developing novel biotechnological applications leveraging aptamers. Aptamers are oligonucleotides with high affinity and specificity for target molecules, presenting substantial potential for therapeutic and diagnostic advancements. The company offers comprehensive aptamer selection services, including SELEX method selection, storage, chemical synthesis, and binding studies. Aptus Biotech's management and technical teams are bolstered by the extensive research and biomedical application experience of the Ramon y Cajal Foundation, complemented by collaborations with other research centers to drive innovation in aptamer technology.
How much funding has Aptus Biotech raised?
Aptus Biotech has raised a total of $3M across 1 funding round:
Private Equity
$3M
Private Equity (2017): $3M with participation from Inveready and Caixa Capital Risc
Key Investors in Aptus Biotech
Inveready
Inveready is a prominent Spanish financial services firm specializing in investment solutions and wealth management. Established in 2008, it has become one of the most active alternative investment firms in Spain, focusing on small and mid-market segments.
Caixa Capital Risc
CriteriaCaixa is a venture capital firm focused on investing in innovative startups at early stages, particularly in technology, biotechnology, and the industrial sector. They manage investments through Caixa Capital Risc and Criteria Venture Capital, directing resources into three specialized funds.
What's next for Aptus Biotech?
With its recent capital infusion, Aptus Biotech is strategically positioned to accelerate the development and commercialization of its aptamer-based solutions. This enterprise-level investment signals a transition towards scaling operations and expanding its market reach. The company's focus on innovative therapeutic and diagnostic tools, supported by robust research collaborations and experienced management, suggests a trajectory towards significant growth and market penetration in the competitive biotechnology sector. Future endeavors will likely involve further clinical validation, strategic partnerships, and broader market adoption of its proprietary aptamer technologies.
See full Aptus Biotech company page
